long-term treatment
Only a       better definition of the subgroups of patients who are more likely to benefit       from long-term treatment, particularly through possible postponement of secondary       OAA failure, will allow a reliable definition of the cost-effectiveness of this       complementary component of anti-diabetic strategy.
Only a       better definition of the subgroups of  @OBJECT$  who are more likely to  @PREDICAT$        from  @SUBJECT$ , particularly through possible postponement of secondary       OAA failure, will allow a reliable definition of the cost-effectiveness of this       complementary component of anti-diabetic strategy.